NCT05751681

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI

Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Patients With Polycystic Ovary Syndrome Undergoing Intra-Cytoplasmic Sperm Injection

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 79 (estimated)
• Sponsor: Zagazig University · Other Government
• Sex: Female
• Age: 20 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

GnRH antagonist protocol is currently a good strategy for controlled ovarian stimulation in women with PCOS undergoing IVF/ICSI cycles. Finding a protocol that can be a better alternative will help in improving the success rate of IVF/ICSI cycles

Detailed description

Progesterone has potent restraint on hypothalamus-pituitary-ovarian axis. It acts on unidentified hypothalamic pulse oscillator neurons. In turn, it acts on gonadotropins releasing hormone (GnRH) secreting neurons leading to inhibition of GnRH secretion. This results in inhibition of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from anterior pituitary. The effect of progesterone appears to decrease GnRH pulse frequency which results in slowing down LH pulse frequency and reducing LH plasma concentrations

Conditions

• Ovary Cyst
• Fertility Issues

Interventions

Type	Name	Description
OTHER	progestin primed ovarian stimulation protocol	progestin primed ovarian stimulation protocol
DRUG	dydrogesterone (Duphaston, Abbott)	20 mg oral dose of dydrogesterone (Duphaston, Abbott)
DRUG	Cetrotide	0.25 mg of Cetrotide (gonadotropin releasing hormone (GnRH) antagonist)

Timeline

• Start date: 2023-02-20
• Primary completion: 2024-04-20
• Completion: 2025-03-20
• First posted: 2023-03-02
• Last updated: 2023-03-02

Locations

1 site across 1 country: Egypt